Expression of USP22 and the chromosomal passenger complex is an indicator of malignant progression in oral squamous cell carcinoma.

aurora-B oral squamous cell carcinoma survivin ubiquitin-specific protease 22

Journal

Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 12 05 2016
accepted: 03 10 2018
entrez: 25 1 2019
pubmed: 25 1 2019
medline: 25 1 2019
Statut: ppublish

Résumé

Oral cancer is a common cancer of the head and neck. Oral squamous cell carcinoma (OSCC) represents almost 90% of the total cases of head and neck cancer. Ubiquitin-specific protease 22 (USP22) is a deubiquitinating hydrolase, and it is highly expressed in various types of cancer, which also typically have a poor prognosis. Aurora-B and Survivin, which belong to the chromosomal passenger complex, are also highly expressed in a number of types of cancer. In the present study, USP22 expression and its associations with Aurora-B and Survivin, and the clinicopathological features in OSCC were explored. USP22 is highly expressed in OSCC. Overexpression of USP22 is associated with lymph node metastasis and histological grade (P<0.01). Additionally, the expression of USP22 was positively associated with Aurora-B (P<0.01), Survivin (P<0.01), and Ki-67 (P<0.01). Furthermore, USP22 small interfering RNA inhibited cell growth and reduced the expression levels of Aurora-B, Survivin and Cyclin B, together with the upregulation of cyclin-dependent kinase inhibitor 1A (p21). These data suggest that USP22, Aurora-B and Survivin promote the OSCC development and may represent novel targets for OSCC diagnosis and treatment in the future.

Identifiants

pubmed: 30675271
doi: 10.3892/ol.2018.9837
pii: OL-0-0-9837
pmc: PMC6341666
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2040-2046

Références

Nat Rev Cancer. 2003 Jan;3(1):46-54
pubmed: 12509766
Curr Opin Cell Biol. 2004 Dec;16(6):708-12
pubmed: 15530785
Biochim Biophys Acta. 2004 Nov 29;1695(1-3):189-207
pubmed: 15571815
Mol Cell Biol. 2005 Jun;25(12):4977-92
pubmed: 15923616
J Clin Invest. 2005 Jun;115(6):1503-21
pubmed: 15931389
Hum Pathol. 2005 Dec;36(12):1281-8
pubmed: 16311121
Science. 2005 Dec 2;310(5753):1499-504
pubmed: 16322459
Gene Expr Patterns. 2006 Mar;6(3):277-84
pubmed: 16378762
Virchows Arch. 2007 Mar;450(3):297-302
pubmed: 17235564
Mol Cell. 2008 Jan 18;29(1):92-101
pubmed: 18206972
Mol Cell. 2008 Jan 18;29(1):102-11
pubmed: 18206973
Cell Cycle. 2008 Jun 1;7(11):1522-4
pubmed: 18469533
Oncol Rep. 2009 Sep;22(3):557-62
pubmed: 19639203
J Cell Biol. 2009 Dec 14;187(6):791-800
pubmed: 19995937
Oral Oncol. 2010 Apr;46(4):263-70
pubmed: 20138567
Mol Cell Biochem. 2011 Jan;346(1-2):11-21
pubmed: 20824490
J Surg Oncol. 2011 Mar 1;103(3):283-9
pubmed: 21337558
Exp Cell Res. 2012 Jul 15;318(12):1407-20
pubmed: 22472345
Oncol Lett. 2012 May;3(5):1109-1114
pubmed: 22783401
Nat Rev Mol Cell Biol. 2012 Dec;13(12):789-803
pubmed: 23175282
PLoS One. 2013;8(2):e55710
pubmed: 23405201
Oncol Rep. 2013 May;29(5):1701-6
pubmed: 23467634
World J Clin Oncol. 2014 May 10;5(2):114-24
pubmed: 24829858
Gene. 2015 Nov 1;572(1):49-56
pubmed: 26143114
Int J Oncol. 2015 Dec;47(6):2208-16
pubmed: 26497847
Front Physiol. 2018 Oct 25;9:1510
pubmed: 30410451

Auteurs

Tian Liu (T)

Department of Pathology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China.
Department of Pathology and Physiopathology, Guilin Medical University, Guilin, Guangxi 541004, P.R. China.

Jing Liu (J)

Department of Pathology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China.
Department of Pathology and Physiopathology, Guilin Medical University, Guilin, Guangxi 541004, P.R. China.

Qiuyue Chen (Q)

Department of Pathology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China.

Shengjian Jin (S)

Department of Pathology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China.
Department of Pathology and Physiopathology, Guilin Medical University, Guilin, Guangxi 541004, P.R. China.

Sisi Mi (S)

Department of Pathology and Physiopathology, Guilin Medical University, Guilin, Guangxi 541004, P.R. China.

Wenhua Shao (W)

Department of Pathology and Physiopathology, Guilin Medical University, Guilin, Guangxi 541004, P.R. China.

Yasusei Kudo (Y)

Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770-8504, Japan.

Sien Zeng (S)

Department of Pathology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China.

Guangying Qi (G)

Department of Pathology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China.
Department of Pathology and Physiopathology, Guilin Medical University, Guilin, Guangxi 541004, P.R. China.

Classifications MeSH